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Part 1 4
What is glaucoma?
 a potentially devastating disease of the eye
 Progressive and irreversible degeneration of retinal ganglion cells(RGC)
 affects mainly people over 40 years of age
Types
open-angle glaucoma 
closed-angle glaucoma
normal tension glaucoma
Global Prevalence of Glaucoma
 One of the main causes of global irreversible blindness 
 The global prevalence of glaucoma(40-80)           3.54%
 POAG in Africa              4.20%
 PACG in Asia 1.09%
 The ratio of men to women for POAG (OR, 1.36)
 The ratio urban areas to rural areas for POAG (OR, 1.58)
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6Risk factors
(intraocular pressure)
(corneal thickness)
symptoms 7
glaucoma
painless
increase in 
IOP
seeing halos 
around 
lights
Progressive 
visual field 
loss
nausea and 
vomiting
Definition of intraocular pressure (IOP) 8
• a balance of aqueous humor production and drainage it.
Possible causes leading to an increase in 
IOP
side-effects 
from 
medications
genetic 
factors
anatomical 
problems
inflammation 
of the eye
9outflow through trabecular meshwork (large arrow) and uveoscleral 
routes (small arrow) and related anatomy. Most aqueous flow is through 
the trabecular meshwork. Each pathway is drained by the eye’s venous 
circulation
aqueous humor Normal flow
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11Disease progression
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• Normal          10-20 mmHg
• In POAG           > 22 mmHg
https://www.digitaleyecenter.com
• In PACG           > 30 mmHg
Diagnosis
Test Name Test explains about 
Tonometry Inner eye pressure 
Gonioscopy Angle Examination
Ophthalmoscopy Dilated eye examination 
shape and color of the optic 
nerve 
Perimetry or Visual 
field test 
Complete field of vision
13Part 2: Glaucoma treatment 
The standard clinical treatment: 
based solely on lowering the intraocular pressure (IOP)
medicines
multiple different eye drops administered 
several times per day
patient compliance is a challenge
progressive visual loss even after IOP 
reduction
laser treatment and surgery
Have risks
often require a combinational approach 
supplementing
additive topical therapies throughout a 
patient’s life
14medicines
Medication class Mechanism of action Drug names 
Alpha-adrenergic agonists aqueous humor production Apraclonidine (Iopidine), 
brimonidine (Alphagan) 
Beta blockers aqueous humor production Betaxolol (Betoptic), 
levobunolol(Betagan)
Carbonic anhydrase inhibitors aqueous humor production Brinzolamide (Azopt), 
dorzolamide (Trusopt) 
Cholinergics Outflow through trabecular
meshwork
Pilocarpine 
Prostaglandin analogues* Outflow through trabecular
meshwork
Bimatoprost (Lumigan), 
latanoprost (Xalatan)
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laser
aims: improving aqueous humor drainage
• argon laser trabeculoplasty (ALT) 
• leading to opening of meshwork
• selective laser trabeculoplasty (SLT). 
• stimulating drainage in the trabecular meshwork
• SLT can be repeated three or four times
• Laser Peripheral Iridectomy
https://slideplayer.com
• most for closed-angle glaucoma
16surgery
• Both laser and conventional surgeries are a temporary solution
• often used when patients are refractory to medical and/or 
laser therapies
• most common method  trabeculectomy
http://www.djo.harvard.edu
• Efficiency         Often up to 2 years 
• The risk of intraocular infections
17Part 3: Gene Therapy in glaucoma 
• an approach of treating diseases
• by modifying the expressions of individual's genes 
• by correction of abnormal genes
• Introducing a new gene into the body to help fight a 
disease.
• This can be accomplished by:
• Replacing a mutated gene that causes disease with a healthy 
copy of the gene.
• Inactivating, or "knocking out", a mutated gene that is 
functioning improperly.
Gene therapy 
18
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• The eye is at the forefront of the application of gene therapy 
techniques to medicine.
• vectors delivered to the eye are relatively isolated from the 
rest of the body
• The size and ease of access to the eye is also favourable 
• allowing small volumes of drug to be precisely delivered
20
Data obtained from the Journal of Gene Medicine database 
http://www.abedia.com/wiley/index.html updated in February 2016. 
The position of eye diseases gene therapy
21
The first gene therapy to be approved by the FDA  
for the eye diseases.
22
• It is one of the first people to undergo gene therapy 
for the treatment of genetic blindness
• The person with it is only able to observe the halo 
of light
• Luxturna is injected into the eye
• The cause is mutation in RPE65 gene
• It is suitable for children right now, because in the 
retina the baby is developing
Source: Dailymail
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• Due to the challenges and side effects of current 
methods
• need for a single injection directly into the eye 
• lead to long-lasting or permanent beneficial 
outcomes
24
One area of great need for eye gene therapy is 
glaucoma, where a long-term gene drug would 
eliminate daily applications and compliance issues. 
25
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Eye diagram adapted from National Eye Institute, National 
Institutes of Health
Diagram showing different ocular target tissues for glaucoma 
gene therapy.
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Glaucoma & genetics
Glaucoma is associated with mutations in 
several genes:
POAG1.MYOC
2.ASB10
3.WDR36 4.NTF4
5.TBK1
6.RPGRIP1
Normal-
tension 
glaucoma 
7.OPA1 8.OPTN
protein gene Gene location characteristics
1 Myocilin(MYOC) MYOC 1q24.3 • Mutations in MYOC are a major cause of 
glaucoma(POAG)
2 ankyrin repeat and SOCS 
box containing 10
ASB10 7q36.1 • is associated with POAG
3 WD repeat-containing 
protein 36
WDR36 5q22.1 • a member of the WD repeat protein family
• The mutation causes POAG
4 NTF4 Neurotrophin4
(NT-4)
19q13.33 • a neurotrophic factor
• signals through the TrkB receptor tyrosine kinase
5 TANK-binding kinase 1 TBK1 12q14.2 • Serine/threonine-protein kinase
• this gene is similar to IKB kinases
6 X-linked retinitis 
pigmentosa GTPase 
regulator-interacting protein
RPGRIP1 14q11.2 • Defects in the gene result in glaucoma
7 Dynamin-like 
mitochondrial protein
OPA1 3q29 • prevents cell death
• Mutations in this gene lead to loss in vision, hearing, 
muscle contraction
8 Optineurin OPTN 10p13 • may play a role in normal-tension glaucoma and POAG
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29Vectors in Gene Therapy
• To transfer the desired gene into a target cell, a carrier is 
required. 
• 2 main classes:
• Viral vectors • Non viral vectors
• Such vehicles of gene delivery are known as vectors. 
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Types of Gene Therapy Vectors
• Retrovirus
• Adeno-Associated Virus(AAV)
• Metalic NPs
 Non-viral vectors 
• Naked DNA
• Liposomes/DNA
• Polymer/DNA complex (polyplex) 
• Liposome/Polymer/DNA
• (lipopolyplex) 
Viral vectors 
 DNA viruses 
• Adenovirus
• Herpes Simplex Virus 
 RNA viruses 
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Vector for Glaucoma Therapy
• a successful gene therapy in the eye need a vector system
• that leads to long, sustained levels of therapeutic gene 
expression within a select target cell
• minimal side effects
• This is particularly important for chronic, long-term 
pathologies such as glaucoma
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• a 4.7 kb single-stranded genome
• recombinant adeno-associated viral vectors (AAVs) 
have proven the most promising
• various vector systems are used for retinal gene therapy
• such as adenovirus, lentivirus, and nanoparticles
• 4.4 kb of the viral genome is deleted
• vectors be packaged with a similar-sized foreign piece 
of DNA
• AAV2 is the most efficient serotype for RGC transduction
33AAV difference with other vectors
https://www.sciencedirect.com
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AAV limitation
• small cargo capacity of AAV vectors for foreign DNA
• large genes are not suitable for use in a standard 
AAV vector
• Splitting large genes into two halves and packing them 
into two independent AAV vectors
• dual vector and more recently triple vector approaches 
are being designed to overcome the coding capacity
• this method is less effective than single AAV-mediated 
gene delivery
35Promoter
• Promoter choice is also important for cell-specific expression 
• lead to  strong  transgene expression within the targeted cell
• between several RGC-specific promoters many designed  
vectors employ:
• CMV (Cytomegalovirus) 
• hybrid CMV early enhancer/chicken b-actin 
promoter (CAG)
• their Advantages small size and high levels of transgene 
expression
36Promoters typically chosen for transduction of retinal ganglion 
cells (RGCs) within the eye.
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• gene therapies for adult-onset glaucoma have focused primarily 
on neuroprotection
(1) by enhancing the activity of innate survival pathways 
in RGC 
(2) by inhibiting the progression of cell death
• involves slowing the loss of RGCs
• This can be accomplished in two ways:
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• Neurotrophic factors promote neuron survival
• During development of the central nervous system
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connections
• only neurons exposed to optimal neurotrophic 
levels survive and establish synaptic connections 
• To control these processes:
• some neurotrophic factors are expressed in 
limited quantities by target tissues
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• in  neurodegenerative diseases:
• Neurotrophic factors as potential neuroprotective 
factors
• brain-derived neurotrophic factor (BDNF) 
• Ciliaryderived neurotrophic factor (CNTF) 
• protect axotomized RGC and RGC in animal 
models of glaucoma
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• The biological effects of neurotrophins are mediated by cell 
surface receptors
• BDNF acts by binding to the receptor tropomyosin-related 
kinase B (TrkB)
• stimulates multiple signalling pathways within RGC
• extracellular signal-regulated kinases 1/2 (Erk 1/2)
• the phosphatidylinositol-3 kinase (PI3K)/Akt 
• Research has shown that intraocular injection of BDNF protein or 
AAV-mediated BDNF expression provides a robust but temporary 
neuroprotective effect on RGC after optic nerve transection or crush
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• the Other approach in glaucoma gene therapy  is inhibition 
the progression of RGC apoptosis
• Caspase activity is the final common element in the 
implementation of apoptosis in RGC
• caspase inhibitors an appealing prospect for neuroprotective 
glaucoma therapies
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• Taking this approach, McKinnon et al:
• injected an AAV-CAG vector expressing a caspase inhibitor
• baculoviral IAP repeat-containing protein-4 (BIRC4)
• one eye on rat models of glaucoma
• BIRC4 was shown to significantly promote RGC survival
• Despite the significant differences in IOP exposure among 
treatment groups 
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• Side effects: Transient conjunctival hyperaemia
• More compounds in this class are being investigated
Rho associated kinase (ROCK) inhibitors:
• ROCK is a serine/threonine kinase
• Rho kinase inhibitors, such as Ripasudil work by inhibition of the 
actin cytoskeleton
• resulting →↑outflow →↓ IOP
• ↑ MMPase expression in TM cells → ECM reorganisation & 
Widening of empty spaces in TM
• ↑intra ocular blood flow, improve RGC survival ,promote axon 
regeneration
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Decreasing Aqueous Humor Production
• Lowering IOP by long-term reduction in aqueous humor production 
may not be an ideal approach to treat glaucoma
• Advantage → the potential for producing a longer lasting effect than 
commercial pharmaceutical products.
• Inhibition of aqueous humor secretion with RNA interference based 
gene therapeutic strategies
• Topical administration of specific siRNAs targeting carbonic 
anhydrase genes and alpha and beta adrenoceptors →↓ IOP in rabbits
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• precise genome editing technologies Have made rapid progress
• provide the possibility of new gene therapy approaches to optic 
nerve diseases
• RNA-guided nucleases (i.e., CRISPR/Cas9)
• designer endonucleases (i.e., TALENs or ZFNs)
• over the coming decade are likely to replace many 
of the current gene supplementation methods
genome editing 
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• CRISPR/Cas9-based therapies have been demonstrated for the 
treatment of optic diseases
• Cas9 creates site-specific double-stranded breaks in DNA
• stimulate host DNA repair mechanisms
• this system requires that two components are expressed in 
cells:
• Cas9 nuclease 
CRISPR/Cas9
• guide RNA (gRNA)
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• The first 20 nucleotides of the gRNA correspond to the DNA 
sequence targeted
• For editing and direct Cas9 to this site using standard RNA–
DNA complementarity base-pairing
• Gene breaks can be repaired through : 
• creates small nucleotide insertions or deletions (indels)
• resulting in a frameshift mutation and termination
• homology-directed repair (HDR)
• in the presence of a donor DNA template
• nonhomologous end joining (NHEJ)
48
https://www.researchgate.net
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• CRISPR/Cas9 can be efficiently delivered to the eye 
using a dual AAV system 
• In a study by Hung et al, a dual AAV2 system was used 
• introduce CRISPR/Cas9 into mouse RGCs in vivo
• achieve knockout of a YFP transgene
• With this dual-vector system, one AAV2 delivered SpCas9
• the other contained a single guide RNA (sgRNA) against YFP
• achieving a knockout rate of 84% in YFP-sgRNA infected 
retinal cells
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• major concern that will need to be assessed
• Possible long-term consequences may include:
• Cas9 activation or repression, and possible epigenetic editing
• long-term AAV-mediated gene expression is beneficial for 
gene supplementation therapies
• CRISPR/Cas9 only requires a short period of expression
CRISPR/Cas9 limitation
• frequency of off-target activity
• modification remains 
51Clinical trials related to glaucoma
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“Sight is the sense which is more valuable than all 
the rest.” So Take care of Eyes!!!
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